ClinicalTrials.gg
Not yet recruitingNCT06867406KPC000154Updated Mar 10, 2025

A Trial to Evaluate KPC000154 Tablets in Healthy Subjects

A Phase 1 interventional study of KPC000154 10mg Tablet Intervention and KPC000154 30mg Tablet Intervention in Healthy Subjects、Lipid Metabolism, sponsored by Kunming Pharmaceuticals, Inc.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Kunming Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KPC000154 Tablets in Healthy Subjects

Read the detailed description

KPC000154 is a thyroid hormone receptor beta (THR-β) agonist that improves NASH by increasing hepatic fat metabolism and reducing fat toxicity. Preclinical studies have shown that KPC000154 significantly reduces lipid levels and liver fibrosis in animal models.

02

Conditions studied

  • Healthy Subjects、Lipid Metabolism
03

In context

Lead sponsor

Kunming Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must fully understand the purpose, nature, procedures of the trial, and potential adverse reactions, and voluntarily participate as subjects, signing an form prior to the commencement of any study procedures.
  2. Healthy male and female subjects aged 18 to 55 years (inclusive of boundary values), with multiple-dose administration trials requiring subjects to have low-density lipoprotein cholesterol (LDL-C) levels that are either close to or at the borderline elevation (i.e., 2.8 mmol/L (110 mg/dL) ≤ LDL-C \< 4.1 mmol/L (160 mg/dL)) are eligible for inclusion.
  3. Male subjects must weigh ≥ 50.0 kg, and female subjects ≥ 45.0 kg; single-dose administration trials require a (BMI) within the range of 19.0-26.0 kg/m² (inclusive of boundary values), while multiple-dose administration trials require a BMI within the range of 19.0-30.0 kg/m² (inclusive of boundary values).
  4. Subjects must utilize effective measures during the trial period and for six months after the last administration of the drug, and must not plan to conceive, donate sperm, or donate ova.
  5. Subjects must be capable of effective communication with the investigators and understand and comply with all requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with an allergic constitution (e.g., known allergies to two or more medications or foods), or a history of allergies to KPC000154 or related .
  2. Individuals with acute illnesses occurring within two weeks prior to screening.
  3. Individuals who have used any medication (including prescription drugs, over-the-counter drugs, traditional Chinese medicine preparations, and herbal remedies), health supplements, or functional vitamins within two weeks prior to screening.
  4. Individuals who have used inhibitors or inducers of , CYP2B6, CYP2C8, CYP2C9, or BCRP within one month prior to screening (e.g., inducers-rifampicin, phenobarbital, carbamazepine, phenytoin; inhibitors-itraconazole, voriconazole, tenofovir, ketoconazole, azithromycin, amiodarone, verapamil, sertraline, perphenazine, thioridazine, dapsone, montelukast, quercetin, phenformin, sulfamethoxazole, tinidazole, clarithromycin, ritonavir, gemfibrozil, clopidogrel, fluconazole, icatibant, aspergillus fumigatus toxin C, neomycin, sulfasalazine, curcumin, elvitegravir, cyclosporine A).
  5. Individuals with a history of chronic or severe diseases affecting the cardiovascular, liver, kidney, respiratory, hematopoietic, lymphatic, endocrine, immune, psychiatric, neurological, or gastrointestinal systems, or individuals with gastrointestinal, liver, kidney, or thyroid diseases that could affect drug absorption or metabolism within one year prior to screening.
  6. Individuals with a history of photosensitivity, or those currently undergoing antibiotic treatment for acne, or those with a history of or currently suffering from immunodeficiency diseases, lupus erythematosus, or immune dysfunction.
  7. Individuals with abnormal clinical significance in physical examination, vital signs, clinical laboratory tests (blood biochemistry tests with > 1.5 times , or AST > 1.5 times ULN, or total > 1.5 times ULN), chest X-ray, cardiac ultrasound (only for multiple-dose trials), abdominal ultrasound (liver, gallbladder, spleen, pancreas, kidneys), and , as assessed by the investigator (Note: In multiple-dose trials, blood biochemistry tests showing borderline elevations in total cholesterol and triglycerides do not constitute abnormalities, i.e., total cholesterol \< 6.2 mmol/L (240 mg/dL), triglycerides \< 3.4 mmol/L (300 mg/dL)).
  8. Individuals who cannot abstain from consuming beverages and foods containing caffeine or alcohol (including chocolate, tea, coffee, cola, etc.), or grapefruit, grapefruit products, dragon fruit, mango, pomelo, orange, starfruit, guava, etc., which affect drug metabolism, or individuals who cannot stop smoking from 48 hours before dosing until the end of the trial.
  9. Individuals with prolonged on ECG at screening: males with QTcF > 450 ms or females with QTcF > 470 ms (corrected by Fridericia's formula, calculated as QTcF = QT/(RR\^0.33)).
  10. Individuals with (GFR) \< 90 mL/min (calculated using the simplified MDRD formula: males: eGFR = 186 × creatinine (mg/dL)\^(-1.154) × age\^(-0.203); females: eGFR = 186 × creatinine (mg/dL)\^(-1.154) × age\^(-0.203) × 0.742); Note: creatinine units are mg/dL, and creatinine results in μmol/L must be converted to mg/dL for calculation, 1 μmol/L = 0.01131 mg/dL.
  11. Individuals with any disease that increases the risk of gastrointestinal bleeding, such as acute gastritis or gastric and duodenal ulcers.
  12. Individuals who have undergone major surgical procedures within six months prior to screening (excluding diagnostic surgeries), or those planning to undergo surgery during the study, or those who have undergone surgeries judged by the investigator to affect drug absorption, distribution, metabolism, or excretion.
  13. Individuals who have received any vaccinations within four weeks prior to screening, or those planning to receive any vaccinations during the trial.
  14. Individuals who have participated in other clinical trials within three months prior to screening (Note: the end time is defined as the last date of participation in the clinical trial).
  15. Individuals who have engaged in blood donation within three months prior to screening, or those who have experienced blood loss (excluding menstrual blood loss) totaling 400 mL or more within six months prior to screening.
  16. Individuals with a history of alcohol consumption, i.e., an average weekly intake exceeding 2 units of alcohol (1 unit = 360 mL of beer or 45 mL of liquor with 40% alcohol content or 150 mL of wine) within one year prior to screening, or those who cannot abstain from alcohol during the trial, or those with alcohol breath test results > 0.0 mg/100 mL.
  17. Individuals with an average daily smoking rate exceeding 5 cigarettes within three months prior to screening, or those with positive cotinine urine tests.
  18. Individuals with a history of drug abuse (including non-medical use of various anesthetics and/or psychotropic drugs) within one year prior to screening, or those with positive drug abuse screening (including morphine, methamphetamine, ketamine, ecstasy (MDMA), marijuana (THC), etc.).
  19. Individuals who cannot tolerate venipuncture/indwelling catheters, or those with difficulties in blood collection, or those with a history of fainting at the sight of blood.
  20. Individuals with swallowing difficulties, or special dietary requirements, who cannot accept uniform diets.
  21. Individuals with hereditary fructose intolerance or glucose/galactose absorption disorders, or those with sucrose-isomaltase deficiency.
  22. Individuals deemed by the investigator to have other conditions unsuitable for inclusion.
  23. Female subjects who have used oral within 30 days prior to screening.
  24. Female subjects who have used long-acting estrogens or progestins (including progesterone-releasing intrauterine devices) or implant contraceptives within six months prior to screening.
  25. Female subjects who have engaged in unprotected sexual intercourse with partners within 14 days prior to screening.
  26. Female subjects with positive pregnancy tests or test results outside the normal range or not within the non-pregnant state range.
  27. Pregnant or lactating women.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (estimated)

Study arms

  • Placebo comparator
    Placebo (SAD)

    A placebo used in a single-dose study where participants receive either the experimental drug or the placebo.

    Drug: Placebo-controlled(SAD)

  • Placebo comparator
    Placebo (MAD)

    A placebo used in a single-dose study where participants receive either the experimental drug or the placebo.

    Drug: Placebo-controlled(MAD)

  • Experimental
    KPC000154 10mg Tablet Intervention

    KPC000154, a thyroid hormone receptor beta (THR-β) agonist, is an investigational drug aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single 10 mg oral dose of KPC000154 tablets in healthy subjects.

    Drug: KPC000154 10mg Tablet Intervention

  • Experimental
    KPC000154 30mg Tablet Intervention

    KPC000154, a thyroid hormone receptor beta (THR-β) agonist, is an investigational drug aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single 10 mg oral dose of KPC000154 tablets in healthy subjects.

    Drug: KPC000154 30mg Tablet Intervention

  • Experimental
    KPC000154 60mg Tablet Intervention

    KPC000154, a thyroid hormone receptor beta (THR-β) agonist, is an investigational drug aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single 10 mg oral dose of KPC000154 tablets in healthy subjects.

    Drug: KPC000154 60mg Tablet Intervention

  • Experimental
    KPC000154 120mg Tablet Intervention

    KPC000154, a thyroid hormone receptor beta (THR-β) agonist, is an investigational drug aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single 10 mg oral dose of KPC000154 tablets in healthy subjects.

    Drug: KPC000154 120mg Tablet Intervention

  • Experimental
    KPC000154 200mg Tablet Intervention

    KPC000154, a thyroid hormone receptor beta (THR-β) agonist, is an investigational drug aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single 10 mg oral dose of KPC000154 tablets in healthy subjects.

    Drug: KPC000154 200mg Tablet Intervention

  • Experimental
    KPC000154 300mg Tablet Intervention

    KPC000154, a thyroid hormone receptor beta (THR-β) agonist, is an investigational drug aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single 10 mg oral dose of KPC000154 tablets in healthy subjects.

    Drug: KPC000154 300mg Tablet Intervention

  • Experimental
    KPC000154 400mg Tablet Intervention

    KPC000154, a thyroid hormone receptor beta (THR-β) agonist, is an investigational drug aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single 10 mg oral dose of KPC000154 tablets in healthy subjects.

    Drug: KPC000154 400mg Tablet Intervention

  • Experimental
    KPC000154 40mg multiple-dose Tablet Intervention(To Be Determined)

    Multiple doses of KPC000154 will be administered to healthy subjects to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.

    Drug: KPC000154 40mg multiple-dose Tablet Intervention(To Be Determined)

  • Experimental
    KPC000154 80mg multiple-dose Tablet Intervention(To Be Determined)

    Multiple doses of KPC000154 will be administered to healthy subjects to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.

    Drug: KPC000154 80mg multiple-dose Tablet Intervention(To Be Determined)

  • Experimental
    KPC000154 120mg multiple-dose Tablet Intervention(To Be Determined)

    Drug: KPC000154 120mg multiple-dose Tablet Intervention(To Be Determined)

Interventions

  • DrugKPC000154 10mg Tablet Intervention

    KPC000154 10mg Tablet administered orally in the morning once daily for 1 day

  • DrugKPC000154 30mg Tablet Intervention

    KPC000154 30mg Tablet administered orally in the morning once daily for 1 day

  • DrugKPC000154 60mg Tablet Intervention

    KPC000154 60mg Tablet administered orally in the morning once daily for 1 day

  • DrugKPC000154 120mg Tablet Intervention

    KPC000154 120mg Tablet administered orally in the morning once daily for 1 day

  • DrugKPC000154 200mg Tablet Intervention

    KPC000154 200mg Tablet administered orally in the morning once daily for 1 day

  • DrugKPC000154 300mg Tablet Intervention

    KPC000154 300mg Tablet administered orally in the morning once daily for 1 day

  • DrugKPC000154 400mg Tablet Intervention

    KPC000154 400mg Tablet administered orally in the morning once daily for 1 day

  • DrugKPC000154 80mg multiple-dose Tablet Intervention(To Be Determined)

    KPC000154 80mg tablet administered orally in the morning for 14 days

  • DrugKPC000154 120mg multiple-dose Tablet Intervention(To Be Determined)

    KPC000154 80mg tablet administered orally in the morning for 14 days

  • DrugKPC000154 40mg multiple-dose Tablet Intervention(To Be Determined)

    KPC000154 120mg tablet administered orally in the morning for 14 days

  • DrugPlacebo-controlled(SAD)

    A placebo used in a single-dose study where participants receive either the experimental drug or the placebo.

  • DrugPlacebo-controlled(MAD)

    A placebo used in a multiple-dose study where participants receive either the experimental drug or the placebo.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic profile of KPC000154 after single and multiple oral administration (Cmax)

    Maximum plasma concentration (Cmax) of KPC000154

    Time frame: 12.8 month

  2. Pharmacokinetic profile of KPC000154 after single and multiple oral administration (AUC0-t)

    Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of KPC000154

    Time frame: 12.8 month

  3. Pharmacokinetic profile of KPC000154 after single and multiple oral administration (Tmax)

    Time to reach maximum plasma concentration (Tmax) of KPC000154

    Time frame: 12.8 month

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    safety measures

    Time frame: 12.8 month

07

Study locations

1 site
  • No.49, Huayuan North Road, Haidian District, Beijing City
    Beijing, Beijing 100191, China
08

References and documents

Publications

  • https://cmab.yiigle.com/uploads/guide_html/%E9%9D%9E%E9%85%92%E7%B2%BE%E6%80%A7%E8%84%82%E8%82%AA%E6%80%A7%E8%82%9D%E7%97%85%E9%98%B2%E6%B2%BB%E6%8C%87%E5%8D%97(2018%E6%9B%B4%E6%96%B0%E7%89%88).html
  • Osaki Y, Takasawa M, Doi K, Nishimura H, Iwaki T, Imaizumi M, Oku N, Hatazawa J, Kubo T. Auditory and tactile processing in a postmeningitic deaf-blind patient with a cochlear implant. Neurology. 2006 Sep 12;67(5):887-90. doi: 10.1212/01.wnl.0000234141.72891.13. PubMed 16966560 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form

Time frame: December 25, 2024 (start date)--January 12, 2026(end date)

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Nov 2025, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 10, 2025
StartEst.
Mar 7, 2025
Primary completionEst.
Nov 30, 2025
CompletionEst.
Jan 31, 2026
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06867406
Lead sponsor
Kunming Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Mar 7, 2025 (estimated)
Primary completion
Nov 30, 2025 (estimated)
Completion
Jan 31, 2026 (estimated)
Last update
Mar 10, 2025

Study contacts

Dongyang D Dr. Liu Dongyang, PhD
Contact
liudongyang@vip.sina.com
18610966092
Fangfang F Dr. Wang Fangfang, PhD
Contact
doctorfancy@126.com
13810103141

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion